The study, carried out over 12 weeks, found that Eriomin from Ingredients by Nature improved two key areas of prediabetes management.
A proactive approach
Published in the Journal of Medicinal Food, the research aimed to evaluate how effectively the standardised extract could reduce blood glucose-related biomarkers.
Participants were divided into two groups at random for the double-blind, randomised, placebo-controlled crossover study. Both groups were given daily doses of the supplement, after which there was a two-week washout period.
They took 200 mg of Eriomin for 26 weeks, after which time the results revealed a 5% reduction in their fasting blood glucose levels. It did this by raising glucagon-like peptide 1 (GLP-1) by 17% and reducing systemic inflammation.
Rob Brewster, President of Ingredients by Nature, says: “We are thrilled to see that Eriomin continues to show its benefits towards managing prediabetes, a prominent health concern for today’s consumer.
“One in three Americans have prediabetes, and 400 million people worldwide are already prediabetic. This study further reveals Eriomin’s ability to be a proactive and multifunctional approach to prediabetes management.”
The new study chose a dose of 200 mg after previous Ingredients by Nature research, Effectiveness of Eriomin in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized controlled study, found the effect of this lower amount was comparable to higher doses of 400 mg and 800 mg.
In the latest study, however, six participants were hyperglycemic (undiagnosed) while all were borderline diabetic. By comparison, those who took part in the previous trial had hyperglycemia bordering on prediabetes.
Brewster adds: “We plan to conduct additional studies with Eriomin to see how it can further benefit those who need alternatives to pharmaceuticals when controlling their blood sugar levels.”
Source: Journal of Medicinal Food
Published online: https://doi.org/10.1089/jmf.2021.0181
‘Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial’
Author: Thais Borges Cesar et al.